BR112023018766A2 - Moduladores alostéricos negativos de ciclopental[c]pirrol de nr2b - Google Patents

Moduladores alostéricos negativos de ciclopental[c]pirrol de nr2b

Info

Publication number
BR112023018766A2
BR112023018766A2 BR112023018766A BR112023018766A BR112023018766A2 BR 112023018766 A2 BR112023018766 A2 BR 112023018766A2 BR 112023018766 A BR112023018766 A BR 112023018766A BR 112023018766 A BR112023018766 A BR 112023018766A BR 112023018766 A2 BR112023018766 A2 BR 112023018766A2
Authority
BR
Brazil
Prior art keywords
cyclopental
nr2b
allosteric modulators
pyrrle
negative allosteric
Prior art date
Application number
BR112023018766A
Other languages
English (en)
Portuguese (pt)
Inventor
Fan Yang
Yaping WANG Kate
Keith Jendza
Matthew Gardinier Kevin
Patrick Healy Mark
Yue Pan
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112023018766A2 publication Critical patent/BR112023018766A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR112023018766A 2021-03-26 2022-03-24 Moduladores alostéricos negativos de ciclopental[c]pirrol de nr2b BR112023018766A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163166516P 2021-03-26 2021-03-26
PCT/US2022/021624 WO2022204336A1 (en) 2021-03-26 2022-03-24 Novel cyclopental[c]pyrrol negative allosteric modulators of nr2b

Publications (1)

Publication Number Publication Date
BR112023018766A2 true BR112023018766A2 (pt) 2023-10-24

Family

ID=83396075

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023018766A BR112023018766A2 (pt) 2021-03-26 2022-03-24 Moduladores alostéricos negativos de ciclopental[c]pirrol de nr2b

Country Status (21)

Country Link
US (1) US20240208953A1 (cg-RX-API-DMAC7.html)
EP (1) EP4313041A4 (cg-RX-API-DMAC7.html)
JP (2) JP7515742B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230160906A (cg-RX-API-DMAC7.html)
CN (1) CN117157072A (cg-RX-API-DMAC7.html)
AR (1) AR125594A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022244367B2 (cg-RX-API-DMAC7.html)
BR (1) BR112023018766A2 (cg-RX-API-DMAC7.html)
CA (1) CA3212203A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023012711A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230458A (cg-RX-API-DMAC7.html)
DO (1) DOP2023000205A (cg-RX-API-DMAC7.html)
EC (1) ECSP23073082A (cg-RX-API-DMAC7.html)
IL (1) IL305601A (cg-RX-API-DMAC7.html)
JO (1) JOP20230236A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023011376A (cg-RX-API-DMAC7.html)
PE (1) PE20250399A1 (cg-RX-API-DMAC7.html)
PY (1) PY2221496A (cg-RX-API-DMAC7.html)
TW (1) TW202304885A (cg-RX-API-DMAC7.html)
UY (1) UY39688A (cg-RX-API-DMAC7.html)
WO (1) WO2022204336A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024387082A1 (en) 2023-11-21 2026-06-04 Fmc Corporation Substituted tetrahydroquinoline and tetrahydroquinoxaline herbicides

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2627010T3 (es) * 2012-07-19 2017-07-26 Janssen Pharmaceutica, N.V. Antagonistas de octahidro-ciclopentapirrolilo de CCR2
US9540324B2 (en) * 2013-09-26 2017-01-10 Luc Therapeutics, Inc. Selective octahydro-cyclopenta[C] pyrrole negative modulators of NR2B
JO3579B1 (ar) * 2014-09-26 2020-07-05 Luc Therapeutics Inc مُعدِلات تفاغرية سالبة لمستقبل nr2b من المركب n-ألكيل أريل-5-أوكسي أريل-ثامن هيدرو-خماسي الحلقة [c] بيرول
WO2017063563A1 (zh) * 2015-10-13 2017-04-20 四川海思科制药有限公司 一种八氢环戊烷并[c]吡咯衍生物及其制备方法和在医药上的用途
CN111481543A (zh) * 2020-05-21 2020-08-04 苏州健雄职业技术学院 Nr2b负变构调节剂联合gaba受体调节剂在制备治疗阿尔兹海默症的药物中的用途

Also Published As

Publication number Publication date
UY39688A (es) 2022-10-31
JP2024509325A (ja) 2024-02-29
PE20250399A1 (es) 2025-02-11
US20240208953A1 (en) 2024-06-27
EP4313041A1 (en) 2024-02-07
JP2024133560A (ja) 2024-10-02
ECSP23073082A (es) 2023-10-31
JP7515742B2 (ja) 2024-07-12
EP4313041A4 (en) 2025-01-15
TW202304885A (zh) 2023-02-01
KR20230160906A (ko) 2023-11-24
CO2023012711A2 (es) 2023-10-19
MX2023011376A (es) 2023-10-06
AU2022244367A1 (en) 2023-09-07
JOP20230236A1 (ar) 2023-09-26
CR20230458A (es) 2023-10-27
PY2221496A (es) 2022-09-29
AU2022244367B2 (en) 2025-04-24
AR125594A1 (es) 2023-08-02
CN117157072A (zh) 2023-12-01
DOP2023000205A (es) 2023-11-15
WO2022204336A1 (en) 2022-09-29
IL305601A (en) 2023-11-01
CA3212203A1 (en) 2022-09-29

Similar Documents

Publication Publication Date Title
BR112014032734A2 (pt) derivados de pirrolidina e seu uso como moduladores da série de reação de complemento
MX2022011365A (es) Derivados de biarilo como inhibidores de la interaccion proteina-proteina de yap/taz-tead.
BR112015029512A8 (pt) derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas
MX2025001619A (es) Inhibidor de pde4b y uso del mismo
AU2014251087B2 (en) Formulations of oxabicycloheptanes and oxabicycloheptenes
BRPI1011657A2 (pt) derivados aminopropiônicos substituídos como inibidores de neprilisina
BR112015016911A2 (pt) tiadiazol, análogos dos mesmos e métodos de tratamento de condições relacionadas à deficiência de smn
BR112015029401A8 (pt) derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
BR112013026257A2 (pt) derivados de glicosídeo e usos dos mesmos para o tratamento de diabetes
BR112013011580A2 (pt) derivados de ácido bisfenil pentanoico substituído por amino como inibidores de nep
EP4595965A3 (en) Heteroalkyl dihydroquinoline sulfonamide compounds
MX2022012898A (es) Ecomposición farmacéutica para administración oral que comprende derivado de aminopirimidina o sal, hidrato o solvato farmacéuticamente aceptable de esta.
BR112021025764A2 (pt) Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo
BR112023016970A2 (pt) Compostos heterocíclicos antivirais
BR112015014292A2 (pt) compostos tricíclicos para inibição do canal de cftr
DOP2019000076A (es) DERIVADOS DE CROMANO, ISOCROMANO Y DIHIDROISOBENZOFURANOS COMO MODULADORES ALOSTÉRICOS NEGATIVOS DE mGluR2, COMPOSICIONES Y SU USO
BR112013026361A2 (pt) derivados de glicosídeo e usos dos mesmos
BR112023002031A2 (pt) Derivados de espiropiperidinila substituídos por heteroarila e usos farmacêuticos dos mesmos
US20080139545A1 (en) Formulation to treat ear infection
BR112019024804A2 (pt) compostos bicíclicos 5,6-fundidos e composições para o tratamento de doenças parasíticas
CO2023012711A2 (es) Nuevos moduladores alostéricos negativos ciclopenta[c]pirrol de nr2b
BR112022024929A2 (pt) Derivados de aminopirimidinila
BR112019007863A2 (pt) derivados de naftiridinona inovadores e seu uso no tratamento de arritmia
AR121828A1 (es) Composición farmacéutica para administración oral que comprende derivado de aminopirimidina o sal farmacéuticamente aceptable, hidrato o solvato de esta
TH2001003481A (th) สารรักษาโรคสำหรับต้อหินซึ่งประกอบรวมด้วย fp อะโกนิสท์และ เบตา -บล็อคเกอร์